Treatment of Thrombosis With Fondaparinux (Arixtra) in a Patient With End-stage Renal Disease Receiving Hemodialysis Therapy
Authors:
- Anjali Alatkar SharathkumarASAnjali Alatkar Sharathkumar
- Christina CrandallCCChristina Crandall
- Jen-Jar LinJLJen-Jar Lin
- Steven PipeSPSteven Pipe
- 1 August 2007
- journal article
- case report
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 29 (8) , 581-584
Abstract
Treatment of thrombosis in children with end-stage renal disease (ESRD) is extremely challenging owing to the underlying risk of bleeding. Fondaparinux (Arixtra, Sanofi-Synthélabo), a synthetic pentasaccharide, is contraindicated in patients with compromised renal function as it is excreted via kidneys. We describe a unique case with ESRD and pulmonary embolism who was treated with fondaparinux owing to the toxicity and poor compliance with low-molecular-weight heparin. Despite regular hemodialysis, a gradual rise in drug levels was observed without significant bleeding complications. This report implies that although low dose fondaparinux can be an option in patients with ESRD under special circumstances, guidelines for laboratory monitoring and appropriate dose adjustments are urgently required to ensure the safety of the patient.Keywords
This publication has 17 references indexed in Scilit:
- Venous Thromboembolism in Patients with Renal Insufficiency: Findings from the RIETE RegistryThe American Journal of Medicine, 2006
- Choosing the Appropriate Antithrombotic Agent for the Prevention and Treatment of VTE: A Case-Based ApproachAnnals of Pharmacotherapy, 2006
- Anti–platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparinBlood, 2005
- Use of fondaparinux (ARIXTRA(R)) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type IINephrology Dialysis Transplantation, 2005
- Efficacy of fondaparinux for thromboprophylaxis in hip fracture patientsThe Journal of Arthroplasty, 2004
- Current and future antithrombotic agents in childrenExpert Review of Cardiovascular Therapy, 2004
- Current anticoagulant therapy—unmet clinical needsThrombosis Research, 2003
- The Pharmacokinetics of Fondaparinux Sodium in Healthy VolunteersClinical Pharmacokinetics, 2002
- Conformation of the pentasaccharide corresponding to the binding site of heparin to Antithrombin-IIICarbohydrate Research, 1987
- Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activityBiochemical and Biophysical Research Communications, 1983